237 related articles for article (PubMed ID: 37482654)
1. Immune-Checkpoint Inhibitors-Induced Type 1 Diabetes Mellitus: From Its Molecular Mechanisms to Clinical Practice.
Cho YK; Jung CH
Diabetes Metab J; 2023 Nov; 47(6):757-766. PubMed ID: 37482654
[TBL] [Abstract][Full Text] [Related]
2. Immune Checkpoint Inhibitors and Risk of Type 1 Diabetes.
Chen X; Affinati AH; Lee Y; Turcu AF; Henry NL; Schiopu E; Qin A; Othus M; Clauw D; Ramnath N; Zhao L
Diabetes Care; 2022 May; 45(5):1170-1176. PubMed ID: 35238899
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in immune checkpoint inhibitor-induced type 1 diabetes mellitus.
Liao D; Liu C; Chen S; Liu F; Li W; Shangguan D; Shi Y
Int Immunopharmacol; 2023 Sep; 122():110414. PubMed ID: 37390646
[TBL] [Abstract][Full Text] [Related]
4. Type 1 diabetes induced by immune checkpoint inhibitors.
Zhang R; Cai XL; Liu L; Han XY; Ji LN
Chin Med J (Engl); 2020 Nov; 133(21):2595-2598. PubMed ID: 32842016
[TBL] [Abstract][Full Text] [Related]
5. Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports.
Zezza M; Kosinski C; Mekoguem C; Marino L; Chtioui H; Pitteloud N; Lamine F
BMC Endocr Disord; 2019 Dec; 19(1):144. PubMed ID: 31870373
[TBL] [Abstract][Full Text] [Related]
6. Type 1 diabetes associated with immune checkpoint inhibitors for malignant melanoma: A case report and review of 8 cases.
Ishiguro A; Ogata D; Ohashi K; Hiki K; Yamakawa K; Jinnai S; Tsutsui K; Takahashi A; Namikawa K; Yamazaki N
Medicine (Baltimore); 2022 Sep; 101(35):e30398. PubMed ID: 36107581
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus.
Hilder R; Tsai K; Quandt Z; Isaacs D; Drakaki A; Xing Y; In GK; Angell TE; Lechner MG
Front Endocrinol (Lausanne); 2023; 14():1242830. PubMed ID: 38027216
[TBL] [Abstract][Full Text] [Related]
8. A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome.
Marsiglio J; McPherson JP; Kovacsovics-Bankowski M; Jeter J; Vaklavas C; Swami U; Grossmann D; Erickson-Wayman A; Soares HP; Kerrigan K; Gibson B; Doherty JA; Hyngstrom J; Hardikar S; Hu-Lieskovan S
Front Immunol; 2023; 14():1229823. PubMed ID: 37671166
[TBL] [Abstract][Full Text] [Related]
9. Type 1 diabetes with immune checkpoint inhibitors: A systematic analysis of clinical trials and a pharmacovigilance study of postmarketing data.
Zhu J; Luo M; Liang D; Gao S; Zheng Y; He Z; Zhao W; Yu X; Qiu K; Wu J
Int Immunopharmacol; 2022 Sep; 110():109053. PubMed ID: 35978507
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
[TBL] [Abstract][Full Text] [Related]
11. [IMMUNE CHECKPOINT INHIBITOR-INDUCED DIABETES MELLITUS].
Fischer M; Amos S; Levy L; Pollack R
Harefuah; 2021 Oct; 160(10):657-662. PubMed ID: 34689435
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review.
de Filette JMK; Pen JJ; Decoster L; Vissers T; Bravenboer B; Van der Auwera BJ; Gorus FK; Roep BO; Aspeslagh S; Neyns B; Velkeniers B; Kharagjitsingh AV
Eur J Endocrinol; 2019 Sep; 181(3):363-374. PubMed ID: 31330498
[TBL] [Abstract][Full Text] [Related]
13. Human adipose-derived mesenchymal stem cells prevent type 1 diabetes induced by immune checkpoint blockade.
Kawada-Horitani E; Kita S; Okita T; Nakamura Y; Nishida H; Honma Y; Fukuda S; Tsugawa-Shimizu Y; Kozawa J; Sakaue T; Kawachi Y; Fujishima Y; Nishizawa H; Azuma M; Maeda N; Shimomura I
Diabetologia; 2022 Jul; 65(7):1185-1197. PubMed ID: 35511238
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes.
Quandt Z; Young A; Anderson M
Clin Exp Immunol; 2020 May; 200(2):131-140. PubMed ID: 32027018
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Inhibitor-Associated Diabetes: A Single-Institution Experience.
Byun DJ; Braunstein R; Flynn J; Zheng J; Lefkowitz RA; Kanbour S; Girotra M
Diabetes Care; 2020 Dec; 43(12):3106-3109. PubMed ID: 33051330
[TBL] [Abstract][Full Text] [Related]
16. Human Leukocyte Antigens and Biomarkers in Type 1 Diabetes Mellitus Induced by Immune-Checkpoint Inhibitors.
Inaba H; Kaido Y; Ito S; Hirobata T; Inoue G; Sugita T; Yamamoto Y; Jinnin M; Kimura H; Kobayashi T; Iwama S; Arima H; Matsuoka T
Endocrinol Metab (Seoul); 2022 Feb; 37(1):84-95. PubMed ID: 35255603
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibitor-Induced Diabetic Ketoacidosis: A Report of Four Cases and Literature Review.
Hong AR; Yoon JH; Kim HK; Kang HC
Front Endocrinol (Lausanne); 2020; 11():14. PubMed ID: 32047478
[TBL] [Abstract][Full Text] [Related]
18. Autoimmune polyendocrine syndrome induced by immune checkpoint inhibitors: a systematic review.
Zhao Z; Wang X; Bao XQ; Ning J; Shang M; Zhang D
Cancer Immunol Immunother; 2021 Jun; 70(6):1527-1540. PubMed ID: 33200250
[TBL] [Abstract][Full Text] [Related]
19. Spontaneous and Immune Checkpoint Inhibitor-Induced Autoimmune Diseases: Analysis of Temporal Information by Using the Japanese Adverse Drug Event Report Database.
Ogawa K; Kozuka Y; Uno H; Utsumi K; Noyori O; Hosoki R
Clin Drug Investig; 2021 Jul; 41(7):615-627. PubMed ID: 34110613
[TBL] [Abstract][Full Text] [Related]
20. Arrhythmic events associated with immune checkpoint inhibitors therapy: A real-world study based on the Food and Drug Administration Adverse Event Reporting System database.
Liu Y; Chen Y; Zeng Z; Liu A
Cancer Med; 2023 Mar; 12(6):6637-6648. PubMed ID: 36426382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
